Latest News and Press Releases
Want to stay updated on the latest news?
-
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for...
-
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
-
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
-
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
-
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological...
-
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous...
-
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...